0001209191-15-079159.txt : 20151110
0001209191-15-079159.hdr.sgml : 20151110
20151109173819
ACCESSION NUMBER: 0001209191-15-079159
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20151105
FILED AS OF DATE: 20151109
DATE AS OF CHANGE: 20151109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Arbuckle Stuart A
CENTRAL INDEX KEY: 0001557290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 151216901
MAIL ADDRESS:
STREET 1: VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY ST.
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-11-05
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001557290
Arbuckle Stuart A
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP\Chief Commercial Officer
Common Stock
2015-11-05
4
M
0
5664
45.11
A
110412
D
Common Stock
2015-11-05
4
M
0
600
77.31
A
111012
D
Common Stock
2015-11-05
4
S
0
2444
122.46
D
108568
D
Common Stock
2015-11-05
4
S
0
2400
123.04
D
106168
D
Common Stock
2015-11-05
4
S
0
1220
124.59
D
104948
D
Common Stock
2015-11-05
4
S
0
200
125.17
D
104748
D
Common Stock
140
I
401(k)
Stock Option (right to buy)
45.11
2015-11-05
4
M
0
5664
0.00
D
2023-02-04
Common Stock
5664
28320
D
Stock Option (right to buy)
77.31
2015-11-05
4
M
0
600
0.00
D
2024-02-04
Common Stock
600
41900
D
Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $122.46 (range $121.84 to $122.82).
Open market sales reported on this line occurred at a weighted average price of $123.04 (range $122.84 to $123.60).
Open market sales reported on this line occurred at a weighted average price of $124.59 (range $124.08 to $124.99).
Open market sales reported on this line occurred at a weighted average price of $125.17 (range $125.13 to $125.21).
The option vests in 16 quarterly installments from 02/05/2013.
The option vests in 16 quarterly installments from 02/05/2014.
Omar White, Attorney-In-Fact
2015-11-09